Amicus Therapeutics Inc (AM6 F) stock market data APIs
€9.1386
0(0%)
as of December 19, 2025
Try our APIs with
free plan!
Amicus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
9.1386
Open
9.1386
High
9.1386
Low
9.1386
52 wk Range
4.8-9.35
Market Cap
2 919 M
Shares Outstanding
309 M
Revenue
599 M
EPS
-0.19
Beta
0.461
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amicus Therapeutics Inc data using free add-ons & libraries
Get Amicus Therapeutics Inc Fundamental Data
Amicus Therapeutics Inc Fundamental data includes:
- Net Revenue: 599 M
- EBITDA: 42 120 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amicus Therapeutics Inc News
New
Assessing Amicus Therapeutics Valuation After a 48.3% One Month Share Price Surge
Wondering if Amicus Therapeutics at around $14 a share is quietly offering real value, or if you are late to the party already? Let's set the stage so you can judge whether this biotech fits your retu...
BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus
We recently published 10 Firms in the Limelight. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best performers on Friday. BioMarin Pharmaceutical extended its winning streak to a third str...
Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger
We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus Therapeutics soared to a new 52-week high on Friday, jumping 3...
Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle
↗️ Oracle (ORCL): TikTok parent Bytedance formally agreed to form a new U.S. joint venture that will be 50% held by an investor consortium that includes Oracle. Shares jumped 6.6%. ↗️ CoreWeav...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
